| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2009 | US20090028820 Antiviral Agent |
| 01/29/2009 | US20090028818 Heterocyclic antiviral compounds |
| 01/29/2009 | US20090028816 Treatment of depression, psychosis, and anxiety |
| 01/29/2009 | US20090028815 Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp |
| 01/29/2009 | US20090028813 Methods for Treating Body Tissue |
| 01/29/2009 | US20090028804 AhR mediators |
| 01/29/2009 | US20090028802 Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same |
| 01/29/2009 | US20090028801 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| 01/29/2009 | US20090028800 Method of Treating Postpartum Depression and Aggression |
| 01/29/2009 | US20090028795 NOD1 as an Anti-Tumor Agent |
| 01/29/2009 | US20090028791 Dichloroacetate Analogs as Imaging Agents |
| 01/29/2009 | US20090028787 Novel Heteroaryl Substituted Benzothiazoles |
| 01/29/2009 | US20090028785 Medical devices with coatings for delivery of a therapeutic agent |
| 01/29/2009 | US20090025719 Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 01/29/2009 | DE4497905B4 Verfahren zur Herstellung von Phencynonat-Hydrochlorid mit α-Konfiguration Process for preparing phencynonate hydrochloride with α-configuration |
| 01/29/2009 | DE202008011653U1 Wirkstoffkombination, kosmetische oder pharmazeutische Zubereitung und Verpackungseinheit Combination of active ingredients, cosmetic or pharmaceutical preparation and packaging unit |
| 01/29/2009 | DE102007037053A1 Hämostyptikum für die minimal-invasive Operation Hemostyptic for minimally invasive surgery |
| 01/29/2009 | DE102007035742A1 Cosmetic and-or dermatological formulation for use, e.g. in stick or roll-on deodorants, contains antiperspirant, mandelic acid, water and polyethoxylated fatty acid of mono-, di- and tri-glyceride |
| 01/29/2009 | DE102007035367A1 Substituierte Aryloxazole und ihre Verwendung Substituted Aryloxazole and their use |
| 01/29/2009 | DE102007035334A1 Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel New substituted Arylsulfonylglycine, their preparation and their use as medicaments |
| 01/29/2009 | DE102007035333A1 Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel New substituted Arylsulfonylglycine, their preparation and their use as medicaments |
| 01/29/2009 | DE102007035323A1 New diazen-1-ium-1,2-diolate substituted ketoconazole derivatives are ergosterol biosynthesis inhibitors useful as an active agent against microbial pathogenic germs, e.g. fungus, and an antiinflammatory active agent |
| 01/29/2009 | DE102007035139A1 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanon und dessen Verwendung als antimikrobieller Wirkstoff 3- (4-hydroxy-3-methoxyphenyl) -1- (4-hydroxyphenyl) -1-propanone and its use as an antimicrobial active substance |
| 01/29/2009 | DE102007034976A1 Arzneimittel zur transdermalen Anwendung bei Tieren For transdermal drug use in animals |
| 01/29/2009 | DE102007034639A1 Mehrteiliges Medizinprodukt Multi-part medical device |
| 01/29/2009 | DE102007034620A1 Neue B1-Antagonisten New B1 antagonists |
| 01/29/2009 | DE102007032393A1 Advanced Glycation Endproducts als Wirkstoffe Advanced glycation end products as drugs |
| 01/29/2009 | DE102004040458B4 Glaskörpertamponadepräparat und seine Verwendung Glaskörpertamponadepräparat and its use |
| 01/29/2009 | CA2731801A1 Therapeutic formulations for the treatment of cold and flu-like symptoms |
| 01/29/2009 | CA2731399A1 Nanoparticle-mediated treatment for inflammatory diseases |
| 01/29/2009 | CA2731398A1 Improved organ protection, preservation and recovery |
| 01/29/2009 | CA2708323A1 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder |
| 01/29/2009 | CA2707858A1 Treatment of post-traumatic stress disorder |
| 01/29/2009 | CA2698271A1 Multikinase inhibitors for use in the treatment of cancer |
| 01/29/2009 | CA2697159A1 Antibodies to cd200 and uses thereof in inhibiting immune responses |
| 01/29/2009 | CA2697137A1 Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly |
| 01/29/2009 | CA2696462A1 use of yeast flakes for treating and/or preventing hyperinsulinemia |
| 01/29/2009 | CA2694479A1 Novel powderous medicaments comprising tiotropium and salmeterol and lactose as carrier |
| 01/29/2009 | CA2694474A1 Novel fluorescent derivatives of polyamine, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumours |
| 01/29/2009 | CA2694443A1 Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
| 01/29/2009 | CA2694440A1 Controlled release interferon drug products and treatment of hcv infection using same |
| 01/29/2009 | CA2694403A1 Topical antibiotic composition for the prevention of lyme disease |
| 01/29/2009 | CA2694386A1 Medicament for transdermal use on animals |
| 01/29/2009 | CA2694343A1 Resveratrol complex and process for the preperation |
| 01/29/2009 | CA2694275A1 Organic compounds |
| 01/29/2009 | CA2694267A1 Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| 01/29/2009 | CA2694261A1 Organic compounds |
| 01/29/2009 | CA2694251A1 Novel b1-antagonists |
| 01/29/2009 | CA2694235A1 Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| 01/29/2009 | CA2694216A1 Benzimidazole derivative |
| 01/29/2009 | CA2694189A1 Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| 01/29/2009 | CA2694009A1 Dual modulators of 5-ht2a and d3 receptors |
| 01/29/2009 | CA2693999A1 Abrasion-resistant and free-flowing glycocyamine-containing moldings and methods for their production |
| 01/29/2009 | CA2693967A1 Heterocyclic amide compounds as protein kinase inhibitors |
| 01/29/2009 | CA2693921A1 Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| 01/29/2009 | CA2693915A1 Pyrazolo[1,5-a]pyrimidine derivatives |
| 01/29/2009 | CA2693901A1 Substituted indazole derivatives active as kinase inhibitors |
| 01/29/2009 | CA2693888A1 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 01/29/2009 | CA2693809A1 Methods of activating irs-1 and akt |
| 01/29/2009 | CA2693804A1 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases |
| 01/29/2009 | CA2693799A1 Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 01/29/2009 | CA2693587A1 Metal complexes incorporated within biodegradable nanoparticles and their use |
| 01/29/2009 | CA2693544A1 Antibacterial combination therapy |
| 01/29/2009 | CA2693377A1 5-pyridinone substituted indazoles |
| 01/29/2009 | CA2693290A1 Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 01/29/2009 | CA2693235A1 Improvements relating to anti-hiv tablet formulations |
| 01/29/2009 | CA2693233A1 Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
| 01/29/2009 | CA2693207A1 Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
| 01/29/2009 | CA2693187A1 New pyrazol derivatives |
| 01/29/2009 | CA2693169A1 N-linked heterocyclic receptor agonists for the treatment of metabolic disorders |
| 01/29/2009 | CA2693163A1 Stabilized tolterodine tartrate formulations |
| 01/29/2009 | CA2692842A1 Use of pactimibe for the preparation of a drug intended to prevent or treat a disease caused by a sebaceous gland dysfunction in humans or animals |
| 01/29/2009 | CA2692824A1 Novel histidine derivatives |
| 01/29/2009 | CA2692161A1 Stabilized immune modulatory rna (simra) compounds |
| 01/29/2009 | CA2691752A1 Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
| 01/29/2009 | CA2690829A1 Formulations of nonopioid and confined opioid analgesics |
| 01/29/2009 | CA2685599A1 Compounds for treating duchenne muscular dystrophy |
| 01/29/2009 | CA2680238A1 Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same |
| 01/28/2009 | EP2019147A1 Novel k04-0144 substances and process for production thereof |
| 01/28/2009 | EP2019138A1 Method of constructing gene transport support |
| 01/28/2009 | EP2019122A1 Polymer conjugate of podophyllotoxin |
| 01/28/2009 | EP2019113A1 New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one |
| 01/28/2009 | EP2019109A1 Trimetal-arene clusters with anticancer activity |
| 01/28/2009 | EP2019102A1 Alkylacetylene substituted Acyltryptophanols |
| 01/28/2009 | EP2019101A1 Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor |
| 01/28/2009 | EP2019100A1 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 01/28/2009 | EP2019099A1 Dpp-IV inhibitors |
| 01/28/2009 | EP2019098A1 Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor |
| 01/28/2009 | EP2019094A1 Heterocyclic type cinnamide derivative |
| 01/28/2009 | EP2019093A1 Urea type cinnamide derivative |
| 01/28/2009 | EP2018875A1 Poorly-water-soluble pharmaceutical agent |
| 01/28/2009 | EP2018874A2 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders comprising a nicotinic compound and an acetylcholinesterase inhibitor |
| 01/28/2009 | EP2018873A1 Prophylactic/therapeutic agent for cancer |
| 01/28/2009 | EP2018872A1 Pharmaceutical product |
| 01/28/2009 | EP2018868A1 Compositions for the treatment and prevention of vertigo and tinnitus including citicoline, ginkgo biloba extract and dimeric flavones of ginkgo biloba |
| 01/28/2009 | EP2018866A1 Pharmaceutical compositions containing voriconazole |
| 01/28/2009 | EP2018865A2 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 01/28/2009 | EP2018864A1 Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| 01/28/2009 | EP2018863A1 Fused heterocyclic compound and use thereof |
| 01/28/2009 | EP2018862A1 Substituted piperidines as therapeutic compounds |